Active-ingredient Dossier
Memantine Hydrochloride
Active-ingredient Dossier for Memantine Hydrochloride (nmda receptor antagonist). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: APO-MEMANTINE
- Brand: MEMANTINE GENERICHEALTH
- Brand: EBIXA
- Brand: MEMANXA
- Brand: Memantine
- Brand: MEMANTINE
- Therapeutic area: Neurology
- Therapeutic area: Uncategorised
What is
Memantine Hydrochloride Memantine Hydrochloride is an nmda receptor antagonist . It is used in the treatment of neurological conditions.
Australian brands containing
Memantine Hydrochloride — APO-MEMANTINE — MEMANTINE GENERICHEALTH — EBIXA — MEMANXA — Memantine — MEMANTINE — MEMANTINE-LAPL — MEMANTINE-WGR — MIMIVA
Therapeutic areas
Memantine Hydrochloride is registered in neurology (8 brands) and uncategorised areas (1 brand) .
Sponsor landscape
The ingredient is marketed by six sponsors: Arrotex Pharmaceuticals, Sun Pharma, Lupin, Lundbeck, Alphapharm, and GM Pharma .
PBS and regulatory activity
Two brands containing memantine hydrochloride have PBS-listed items, with the latest PBS schedule date of 1 May 2026 . The latest PBAC outcome on record is from 1 March 2008, and there are no AusPARs on record for this ingredient .